AspireNCT06617429
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 17 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Lack of efficacy Show 4 more changesShow less
- Study completion date changed from estimate of Nov 2027 to Oct 30, 2026
- Eligibility criteria expanded, about 14 words
- Secondary endpoints: details revised at 1 of 9 entries
- Site details revised at 6 of 28 sites
- Minor Primary completion date changed from estimate of Jul 2026 to Jul 10, 2026v19
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 120 to confirmed 129
- Study sites: 31 to 28
- Study title expanded, about 2 words
- Minor Study sites revised (31)v14
- Minor Study sites revised (31)v13
Show 11 earlier versionsHide 11 earlier versions
- Minor Study sites revised (31)v12
- Minor Study sites revised (31)v11
- Minor Study sites: 30 to 31v10
- Minor Study sites: 29 to 30v9
- Minor Study sites revised (29)v8
- Minor Study sites: 28 to 29v7
- Minor Eligibility criteria shortened, about 77 words
- Secondary endpoints: 6 to 9
- Study sites revised (28)
- Minor Study sites revised (28)v5
- Minor Study sites: 29 to 28v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 29
- Start date changed from estimate of Dec 2024 to Dec 3, 2024
- Minor Study sites: 0 to 1v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from Baseline in Bayley-4 Cognitive Raw Score Without Caregiver Input at Day 338
Timeframe: Baseline, Day 338
Secondary (9)
Net Response in Multidomain Responder Index (MDRI)
Change from Baseline in ABC-C Hyperactivity/Noncompliance Subscale Score at Day 338
Change from Baseline in Bayley-4 Receptive Communication Raw Score at Day 338
Change from Baseline in Angelman Severity Assessment (ASA) Sleep Rating Raw Score at Day 338
Change from Baseline in Vineland Adaptive Behavior Scales-3 (Vineland-3) Receptive Communication Raw Score at Day 338
Show 4 moreShow less
Change from Baseline in Vineland-3 Expressive Communication Raw Score at Day 338
Change from Baseline in Bayley-4 Gross Motor Raw Score at Day 338
Change from Baseline in ASA Gross Motor Rating at Day 338
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Severity of AEs and Relationship to Investigational Drug, Procedure, and Premedication
Arms and interventions
GTX-102Experimental
Participants will receive GTX-102 via lumbar puncture (LP) during both the double-blind and open-label period
Sham-LP then GTX-102Sham comparator
Participants will receive sham procedure during the double-blind period and then will receive GTX-102 via LP during the open-label period
Drugs: GTX-102
Procedures: Sham-LP
Sites
28 sites in 6 countries
United States 14, Spain 4, Germany 3, Japan 3, Canada 2, Poland 2